

### Backed by direct evidence base demonstrating efficacy on key clinical and health economic outcomes



Antibiotic prescriptions reduced by 39% (P=.04)<sup>15</sup>

high-risk patient over 6 months\*\*\*15

## Nutricia as your partner of choice for pioneering innovative patient-centric medical nutrition

- Fortimel Compact Protein (125ml) is a Nutricia original innovation which was 'first of its kind'
- Proudly developed to answer the demands for a high protein, high energy formula in a low volume, specially developed for patients suffering from DRM, in particular patients with poor appetite alongside high protein needs.
- Nutricia support continuous investment in Fortimel Compact Protein evidence base, demonstrating efficacy in key clinical and health economic outcomes 15-21.
- Including 5 sensory adapted and tailored flavours, designed specifically for oncology patients with taste alterations, Fortimel Compact Protein range now offers one of the most extensive flavours ranges on the market\*\*\*\* (12 flavours in total).



Fortimel Compact Protein is a food for special medical purposes (FSMP), for the dietary management of disease related malnutrition. It must be used under medical supervision only

#### References

- Schuetz P, et al. Clin Nutr. 2020 Nov;39:3361-3368. Cawood AI, et al. Ageing Res Rev. 2012;11:278-96. Bauer J, et al. J Am Med Dir Assoc. 2013;14:542-59. Volkert D et al. Clin Nutr. 2022;41:958-989. Gomes F, et al. 2018;37:336-353. Muscaritoli M, et al. Clin Nutr. 2021;40:2898-2913. Weimann A, et al. Clin Nutr. 2017;36:623-650. Lochs H, et al. Clin Nutr. 2006;25:180-6. Schuetz P, et al. Lancet. 2019; 8:2312-2321. I Hubbard GP, et al. Clin Nutr. 2012;31:293-312.

- Hubbard GP et al. Proc. Nutr. Soc. 2010; 69; OCE2: E164. 5. Freeman R et al. Ageing Clin Exp Res. 2011; 23; 1:159 Phillips SM. Front Nutr. 2017;4:13.
- Brown F. et al. 2020:24:305-3

- Ter Wee P, et al. 2016;20:944-951. Smith TR, et al. Nutrients. 2020;12:517. Frederiksen AKS, et al. Clin Nutr Open Sci. 2022;42:148-149 Grönstedt H, et al. J Am Med Dir Assoc. 2020;21:1229-1237. Grupińska J, et al. Nutrients. 2021;3:3549. Zietarska M, et al. Nutrients. 2017;11:1108.
- hway.co.uk/downloads/Managing Malnutrition.pdf [Accessed July 2022]



# AN INNOVATIVE, EVIDENCE-BASED, ORAL **NUTRITIONAL SUPPLEMENT DESIGNED TO** MEET HIGH PROTEIN DEMANDS IN PATIENTS WITH DISEASE-RELATED MALNUTRITION

Are you overlooking simple solutions to address the challenging protein gaps?





<sup>\*\*</sup>Primary intervention was not met in full intervention group<sup>18</sup>. Sub-group analysis of those with higher adherence to the intervention (£40% compliance to the combined intervention of ONS plus exercise) increased their fat free mass (\$\subsection 2.12 kg\), vs control (CG) P 0.007\). Logistic regression analyses indicated that the odds ratio for maintained/improved 30-second Chair Stand Test was 3.5 (P 0.034) among the participants with higher adherence compared with the CG.
\*\*\*\*Calculation based on Brown et al.<sup>18</sup> Implementation of the UK malnutrition pathway<sup>22</sup> including 2 Fortisip Compact Protein per day for patients at high risk of malnutrition. GBP converted to Euro and rounded down, £997.02 = approx.1000 Euro.

<sup>\*\*\*\*</sup> for patients at risk of, or malnourished who require products registered as FSMP in the EU.

#### Understanding the importance of early and assertive high protein intervention...

The prevalence of disease related malnutrition (DRM) is consistently high across the patient journey;¹



1/4 hospital patients<sup>1</sup>










1/3 oncology patients<sup>1</sup>

1/3 community older

1/3 care home patients<sup>1</sup>

Left unmanaged, DRM can lead to serious consequences which impact on a patient's recovery, independence and quality of life<sup>2,3</sup>







Reduced mobility and independence4



Increased complications; infections and delayed wound healing<sup>3-5</sup>



Increased length of hospital stay (LoS) and cost of care<sup>3-5</sup>

Early and assertive provision of high-quality protein is an essential component of successful DRM intervention strategies<sup>4,6</sup>;



Daily Guideline Recommendations: (e.g. Polymorbid, Oncology, Geriatrics, Surgery)4-8 1-1.5g/kg/day

"High protein formulae contain 20% or more of total energy from protein" ESPEN<sup>5,9</sup>

Latest guidelines recommend significantly more protein compared to healthy populations<sup>4-8</sup>

#### Let's take a closer look at just how big the protein gap can be...

#### Case example\*:



Admitted to hospital with suspected infection and fall at home

Age: 72 years\*


Weight: 70kg\*

BMI: 25kg/m<sup>2\*</sup>

Screened for malnutrition:

High risk

(NRS ≥3, or MUST ≥2)



- Dietitian referral is indicated for full assessment and individualized dietary intervention
- Ensure assertive use of high protein oral nutritional supplements (ONS) to optimise clinical outcome

## Before deciding on a suitable ONS prescription, first consider the common adherence barriers faced by patients with DRM<sup>2</sup>

Patients with DRM often struggle to finish a standard 200ml ONS<sup>11-13</sup> due to multiple barriers<sup>5,11</sup>;



Poor appetite and early satiety

Fatigue and shortness of breath


- Taste changes and nausea
- Limited variety of ONS flavours

DRM Patie


Evidenced-based ONS specially designed to help meet the nutritional gap and overcome adherence barriers will lead to improved patient outcomes....

#### Don't forget... Not all ONS are the same!

A high protein, high energy, low volume ONS can drive better adherence, and ultimately, better patient outcomes



High protein ONS result in improved outcomes such as increased grip strength, improved body composition, reduced complications (e.g. wound healing, infections) and LoS<sup>3</sup>















<sup>\*</sup>Data taken from Effort trial - average baseline values for patients at high risk of malnutrition in hospital<sup>10</sup>